Within this study, we designed and synthesized four new oxime compounds of the N-substituted 2-hydroxyiminoacetamide structure and evaluated their interactions with acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Our aim was to explore the possibility of extending the dual-binding mode of interaction between the enzyme and the inhibitor to a so-called triple-binding mode of interaction through the introduction of an additional binding moiety. N-substituted 2-hydroxyiminoacetamide 1 was prepared via BOP catalyzed amidation of hydroxyiminoacetic acid with 3-azido-1-phenylpropylamine. An azide group enabled us to prepare more elaborate structures 2 -4 by the copper-catalyzed azide-alkyne cycloaddition. The new compounds 1 -4 differed in their presumed AChE peripheral site binding moiety, which ranged from an azide group to functionalized heterocycles.
Introduction
Acetylcholinesterase (AChE; EC 3.1.1.7) is a key enzyme for the regulation of cholinergic transmission in both the central and peripheral nervous system that catalyzes the hydrolysis of the neurotransmitter acetylcholine (ACh) [1] . The decline of hippocampal and cortical levels of ACh is a characteristic of Alzheimer's disease (AD), a disabling and fatal neurodegenerative disease manifested by memory loss and learning deficits [2] . Thus, today's drugs designed for the treatment of AD are reversible AChE inhibitors that block the enzyme active site leading to an increase of ACh levels and, in turn, to the alleviation of disease symptoms [3] .
The active site of AChE is a 20 Å deep gorge divided into two sub-sites; the peripheral anionic site (PAS) (Tyr72, Tyr124, Trp286) located at the entrance of the gorge, and the catalytic site (CAS) located close to the bottom of the gorge. CAS is composed of the catalytic triad (Ser203, His447, Glu334), an oxyanion hole (Gly121, Gly122, Ala204), an acyl-binding pocket (Phe288, Phe290) and a choline binding site (Trp86, Tyr337, Phe338) [4, 5] . The two sub-sites serve as the recognition sites for the ligands that bind to the AChE governing their mechanism of interaction. Depending on the established interactions, ligands can be described as PAS-binding or the CAS-binding. Out of several anti-AD drugs ( Fig. 1) , galanthamine (half-maximal inhibitory concentration (IC 50 ) of 2.01 μmol/L in human AChE) [6, 7] and huperzine A (IC 50 of 0.082 μmol/L in mouse AChE) [8, 9] bind to the CAS, while propidium iodide (IC 50 of 1.1 μmol/L in mouse AChE) [10] binds in the PAS region [11] .
Inhibitors that bind to PAS and CAS simultaneously include both symmetrical (e.g. bistacrine, K d of 250 nmol/L in fetal bovine serum AChE) [12, 13] and non-symmetrical tacrine analogues (e.g. syn-TZ2PA6, K d of 0.41 nmol/L in mouse AChE) [14, 15] , as well as donepezil (K d in hAChE of 3.35 nmol/L (R-donepezil), 17.5 nmol/L (S-donepezil)) an anti-AD drug that binds with a basic nitrogen in the CAS and an aromatic system in the PAS [16, 17] . Crystal structures of AChE-inhibitor complexes have shown that inhibitors usually interact with gorge residues via arene-arene (π-π) interactions.
Trp86, which is essential for the interaction with the trimethylammonium group of ACh, is considered crucial for the stabilization of CAS-binding ligands through cation-π and π-π interactions together with the Tyr337, and His447 of the catalytic triad [18] [19] [20] . On the other hand, PAS-binding ligands are stabilized through π-π interactions with Tyr72, Tyr124, and Trp286 [21-23].
The acute toxicity of organophosphorus (OP) nerve agents (e.g. tabun, soman, sarin, VX) is due to their irreversible inhibition of AChE by covalently binding to the catalytic serine residue which results in the accumulation of ACh in synaptic clefts [24] . The activity of AChE can be restored by 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 3 treatment with a reactivator from the quaternary pyridinium oxime family (2-PAM, trimedoxime, obidoxime, HI-6, Hlö-7) (Fig. 1) by cleaving the covalent bond between the catalytic serine residue and the nerve agent [25, 26] . HI-6 (K I for hAChE of 20 μmol/L) [27] is an example of a quaternary bispyridinium oxime that binds to both the CAS and the PAS with its two positively charged heterocyclic aromatic rings [28] . The efficacy of both AChE inhibitors and reactivators currently used in medical treatment of AD or OP nerve agent poisoning is limited because they do not cross the blood-brain barrier readily due to their permanent positive charge [29] .
Butyrylcholinesterase (BChE, E.C. 3.1.1.8) is related to AChE and it can also catalyze the hydrolysis of ACh; moreover, it serves as a co-regulator of cholinergic neurotransmission [30, 31] .
However, BChE plays an important role in the pathogenesis of AD with its activity increased at the early stage of disease and involvement in the amyloid β-peptide aggregation developing into senile plaque deposits [32, 33] . The inhibition of BChE may thus be beneficial in the medical treatment of AD patients. AChE and BChE show a high resemblance with sequence homology of 65 % [33, 34] .
However, their active sites display different amino acids composition and therefore the BChE active site is about 200 Å 3 bigger [35, 36] , consequently allowing the BChE to bind and hydrolyze larger ligands and substrates than AChE [37] . Moreover, differences between AChE and BChE active site amino acid composition lead to AChE/BChE selectivity for many ligands and substrates [23, 38] . Some of the selective AChE inhibitors are BW284C51, huperzin A, and the aforementioned donepezil [8,17,24,23,] . Several selective BChE inhibitors have also been described, including bambuterol and ethopropazine ( Fig. 1 ) [39] [40] [41] [42] [43] . Using ChE active site differences for designing selective inhibitors could help develop improved AD drugs and reactivators of OP nerve agent-inhibited enzymes.
In this study, we designed and synthesized four new compounds to probe the possibility of simultaneous non-covalent triple-binding between the inhibitors and the ChE. Our results could lead to the discovery of more selective ChE inhibitors as well as more effective reactivators of OP nerve agentinhibited enzymes. Compounds were designed by modifying the structures of N-substituted 2-hydroxyiminoacetamides, recently introduced non-charged AChE oxime reactivators [44, 45] , through the introduction of a phenyl ring. It was expected that the phenyl ring would help their stabilization through π-π interactions with active site aromatic amino acids and provide additional binding moiety apart from PAS-moiety and the 2-hidroxyiminoacetamide group. The working hypothesis was that the phenyl ring would interact with the choline binding site directing, together with PAS-binding moiety, the 2-hidroxyiminoacetamide group into a so-called third binding site surrounding Ser203. Molecular 4 modelling was used to determine and visualize the binding modes of the new compounds and their interactions with the enzymes. (4) were synthesized. 1 was prepared via BOP catalyzed amidation of hydroxyiminoacetic acid with 3-azido-1-phenylpropylamine [46] . 2-4 were prepared by copper catalyzed azide-alkyne cycloaddition starting from 1 and a corresponding alkyne:
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imidazole-2-carbaldehyde oxime, respectively [47, 48] . For more detailed information about the synthesis of 1-4, please refer to the Supplementary material. 
In vitro enzyme inhibition studies
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DMSO on the degree of enzyme inhibition, the final content of DMSO was held constant whenever it exceeded 0.05 %.
The inhibition constants were evaluated by the Enzyme Kinetics module of Graph Pad Prism version 6.01 (GraphPad Software, Inc., USA). The dose response curves were fitted using the Mixed Model Inhibition equation:
where S is the concentration of substrate ATCh, I is the concentration of inhibitor (oxime), K I is the enzyme-oxime inhibition (dissociation) constant of a complex formed at the catalytic site, αK I is the Michaelis complex-oxime inhibition (dissociation) constant of a complex formed at the peripheral site, K m is a dissociation constant of the Michaelis complex, and V m is maximal activity.
Molecular modelling
Compounds to be docked in the active site of human AChE and human BChE were created and minimized using the MMFF94 force field implemented in ChemBio3D Ultra 12.0 (PerkinElmer, Inc., USA).
Accelrys Discovery Studio's Dock Ligands protocol (CDOCKER) was used for the docking study with CHARMm force field (Accelrys, USA) [50, 51] . The crystal structure of human AChE (PDB: 1B41, 4PQE) [52] or human BChE (PDB: 2PM8) [53] was used as the rigid receptor. The binding site within the AChE or BChE was defined as the largest cavity in the enzyme structure surrounded by a sphere (r = 13 Å). The following steps were included in the CDOCKER protocol.
First, a set of 20 random ligand conformations for each test compound was generated. In the following step, 20 random orientations were kept if the energy was less than the specified threshold value of 300 vdW. This process continued until either a desired number of low-energy orientations were found or the maximum number of bad orientations had been attempted. The maximum number of bad orientations was set to 800. In the next step each orientation was subjected to simulated annealing molecular dynamics. The temperature was increased to 700 K then cooled to 310 K. The numbers of heating and cooling phase steps during simulated annealing were set to 2000 and 5000, respectively.
For the simulated annealing refinement, grid extension (8.0 Å) was used. In the subsequent step, a final 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 6 minimization of each refined pose of the ligand in the rigid receptor is performed using full potential. Molecular Volume implicit solvent model was used [54, 55] . The non-polar surface area was used to approximate the non-polar component of the solvation energy. Implicit solvent dielectric constant was set to 80. Distance cutoff value used for counting non-bonded interaction pairs was set to 14.0 Å.
Results and discussion
Kinetic measurements
Based on the hypothesis that the dual-binding mode of interaction between AChE/BChE and its inhibitors or reactivators can be extended to a so-called triple-binding mode of interaction, we designed and synthesized four new compounds capable of simultaneous non-covalent triple-binding with enzymes. In doing so, we modified the structures of recently reported N-substituted 2-hidroxyimnoacetamides [44] by introducing the phenyl ring. Some of the reported N-substituted 2-hidroxyiminoacetamides are known to possess high reactivation potential toward sarin-, cyclosarin-, and VX-inhibited AChE [45] . According to our hypothesis, the phenyl ring was expected to bind in the choline binding site. The presumed PAS-binding moieties ranged from an azide group to functionalized heterocycles and were connected with the central N-(1-phenylpropyl)-2-hydroxyiminoacetamide scaffold via a 1,2,3-triazole ring.
Following N-substituted 2-hydroxyiminoacetamides were
, and 2-hydroxyimino-N-(3- (Fig. 2) .
To determine the binding affinity of AChE and BChE for 1-4, we performed detailed enzyme kinetics measurements (Fig. 3 ). All four of the N-substituted 2-hydroxyiminoacetamides reversibly inhibited both AChE and BChE displaying mixed types of inhibition. This suggests that all four oximes 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7 can bind to the free enzyme (E) and to the Michaelis complex (ES). Parameter α > 1 describes the decrease in the ES complex affinity for an oxime in comparison to the affinity of the free enzyme (E).
All of the tested oximes bind more weakly to the ES than to the E in the case of AChE, except for 2.
However, due to the low solubility of 2 in 0.1 M sodium phosphate buffer, its kinetic parameters could not be evaluated at the optimal concentration range which may explain its exceptional behavior. For BChE, this decrease in ES affinity is even more pronounced indicating obstruction of interactions between the oxime and gorge residues due to the substrate presence. Inhibition constants (K i ) for AChE ranged from 50 to 1200 μmol/L (Table 1) with the inhibition potency increasing in the following order: binding to BChE, probably due to a bigger BChE active site compared to AChE allowing such bulkier ligands to adopt more favorable binding conformation [37] . Also, 6 out of 14 aromatic amino acids in the AChE active site corresponding to aliphatic ones in the BChE site made it more hydrophobic and favorable for lipophilic compounds. Moreover, 3 displayed an almost 150 times higher affinity for BChE compared to AChE, thus 3 can be considered a selective BChE inhibitor.
Molecular modeling
In order to reveal the key interactions leading to the observed differences in binding affinity of 1-4 and their preference for binding to BChE, molecular docking studies were conducted using structures of human AChE (PDB: 1B41, 4PQE) and human BChE (PDB: 2PM8) (Fig. 4 and 5 ). 1-4 were docked into the active site of the enzyme. The resulting poses were critically investigated targeting the ones including π-π interactions between a compound and aromatic amino acids of PAS and choline binding sites -a type of interaction typical of enzyme-inhibitor/reactivator complex observed by X-ray crystallography for both AChE and BChE [12, [18] [19] [20] [21] [22] [23] 28, 56, 57] . Poses that had fulfilled these criteria were chosen for the prediction of key interactions between the compound and the enzyme summarized in Table 2 . In agreement with experimentally determined enzyme-N-substituted 2-hydroxyiminoacetamide inhibition constants, 3 displayed the highest number of predicted interactions with both enzymes, while the weakest inhibitor 1 displayed the lowest number of interactions. On the 8 other, it was clear that the differences in inhibition potencies and their preference for binding to BChE could not be attributed solely to the number of interactions with the enzyme.
Modeling of AChE complexes
The predicted binding geometry of 1 in the AChE active site supported our hypothesis that a phenyl ring would bind in the choline binding site yielding π-π interactions with Trp86 (Fig. 4A) π-π stacking of the tacrine ring against the Trp84 in the tacrine-TcAChE complex [59] and bistacrineTcAChE complex [13] , and against the Trp82 in the tacrine-hBChE complex [56] . Also in accordance with our hypothesis, the 2-hydroxyiminoacetamide moiety was directed toward the catalytic serine Ser203 making hydrogen bonds between its hydroxyl group and Ser203 and/or His447 of the catalytic triad. Additionally, a side chain of 1 with an azide group makes hydrogen bonds with Tyr133. This residue makes hydrogen bonds with ligands, i.e. (-)-huperzine A in complex with hAChE [56] . The lack of interactions between 1 and the residues in the PAS region could explain its low inhibition potential when compared to other N-substituted 2-hydroxyiminoacetamides.
Model complex of 2 and AChE (Fig. 4B ) also predicts π-π interactions between the phenyl ring and Trp86. The triazole ring, absent in 1, makes hydrogen bonds with Tyr124 which is similar to a hydrogen bond between the phenol ring of Tyr124 and the pyridinium ring of the 2-hydroxyiminomethylpyridinium ring of HI-6 in complex with mAChE [60] . These interactions seem to govern the overall binding mode of 2 in the AChE active site directing the presumed PAS-binding moiety, i.e.
the cyclopentyl ring, in the PAS and the 2-hydroxyiminoacetamide moiety toward the catalytic serine with which it makes hydrogen bonds via its oxime group [57] .
Elongated binding conformation of 3 in the AChE active site (Fig. 4C ) is characterized with a methylimidazole ring, directed towards the entry of the AChE gorge and the 2-hydroxyiminoacetamide moiety directed towards the bottom of the gorge. The geometry of 3 in the AChE gorge leads to multiple π-π interactions with aromatic amino acids; the imidazole ring with Trp286, the triazole ring with Tyr341 and with Phe297 (π-sigma interaction), and the phenyl ring interacts with Tyr124. This is in accordance with X-ray structures of oximes HI-6, Ortho-7, and obidoxime in complex with mAChE [58] , and donepezil in complex with TcAChE [17] . Additionally, the 2-hydroxyiminoacetamide moiety of 3 creates a hydrogen bond with Glu202. The predicted binding geometry of 4 in the AChE (Fig. 4D) suggests that 4 also binds with its presumed PAS-binding moiety, imidazole-2-carboxaldehyde oxime, at the entry of the gorge and the phenyl ring at the choline binding site. The triazole ring binds in the narrow part defined by Tyr124 and Tyr337. The only difference between the predicted binding geometry of 3 and 4 was that 4 had been buried deeper in the AChE active site. This results in π-π interactions between the imidazole-2-carboxaldehyde oxime and Trp341. Additionally, 2-hydroxyiminoacetamide group makes hydrogen bonds with Glu202 and Ser203. However, this also leads to the loss of interaction between the imidazole ring and PAS residues Tyr124 and Trp286 which could explain the lower inhibition potential of 4 when compared to 3.
Modeling of BChE complexes
The most commonly observed change in the predicted binding geometry of 1-4 in the BChE active site when compared to those for AChE has to do with the energetically more favorable bended conformations of oximes in the BChE active site, a finding which reflects the larger BChE active site volume. The complex of 1 in the BChE active site (Fig. 5A ) again supports our hypothesis that a phenyl ring would bind in the choline binding site making π-π interactions with Trp82. However, in the BChE active site the phenyl ring is placed closer to the center of the choline binding site. This change in the positioning of the phenyl ring is made possible because bulky Tyr337 in the AChE corresponds to smaller Ala328 in the BChE. Additionally, the side chain modified with an azide group is oriented almost parallel to the Trp82 main chain making π-π interactions with its indole ring and the 2-hydroxyiminoacetamide moiety is directed towards Ser203 making multiple hydrogen bonds. Once again, the lack of interactions between 1 and the residues in the PAS region could explain its lowest inhibition potential among all of the tested compounds.
The complex of 2 and BChE (Fig. 5B ) predicts binding for 2 almost perpendicularly to the axis connecting the entry and the bottom of the active site gorge. This orientation is made possible because aromatic Tyr124, Phe297, and Tyr337 in the AChE active site correspond to smaller Gln119, Val288, and Ala328 in the BChE active site, respectively. Otherwise, these aromatic amino acids in the AChE active site would not allow such an orientation of 2. Thereby, the cyclopentyl ring occupies the space normally inaccessible in the AChE active site. 2-hydroxyiminoacetamide moiety is directed towards the acyl pocket with its hydroxyl group and making hydrogen bonds with Leu286. Additionally, the carbonyl oxygen of the 2-hydroxyiminoacetamide moiety makes hydrogen bonds with Ser198.
Contrary to our hypothesis, the phenyl ring is shifted towards the entry of the BChE active site gorge, 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 but is just close enough to Phe329 to make a π-π interaction. This distinct residue corresponds to Phe338 in the AChE active site which participates in aromatic interactions, the donepezil complex with TcAChE [17] and the HI-6 complex with mAChE [60] .
Model complex of 3 and BChE (Fig. 5C ) predicts geometry where 3 is in a bended conformation and is placed in the center of the BChE active site. Once again this is expected due to Gln119, Val288, and Ala328. Thereby, the methylimidazole ring occupies the volume otherwise restricted in the AChE active site because of the Tyr337 side chain and interacts with Trp82 and
His438 via π-π interactions. The 2-hydroxyiminoacetamide moiety is directed towards the bottom of the active site where its amide hydrogen makes hydrogen bonds with the backbone of Pro285 and the oxime group makes hydrogen bonds with Gly116 and Gly117 from an oxyanion hole, as well as with Ser198. It has been assumed that hydrogen bonding with Pro285 has been partially responsible for the inhibition differences of horse, human, and mouse BChE [41] .
The complex of 4 and BChE (Fig. 5D) shows that the imidazole-2-carboxaldehyde oxime and the following triazole ring are located in the upper part of the active site while the phenyl ring and the 2-hydroxyiminoacetamide moiety are located close to the bottom of the active site. Such positioning of the triazole ring allows it to make π-π interactions with Tyr332 that corresponds to Tyr341 in the AChE site. In support of our hypothesis, the phenyl ring was placed at the bottom of the BChE active site close enough to yield a π-π interaction with Trp82. This distinct tryptophan residue is also involved in π-sigma interaction with a hydrogen atom from one of the 4 methylene groups and Trp82 main chain makes a hydrogen bond with the hydroxyl group of the 2-hydroxyiminoacetamide moiety. The former interaction could be related to that between the methylene group in the tetrahydroazepine ring of (-)-galanthamine in complex with TcAChE [57] . The 2-hydroxyiminoacetamide moiety is located close to the center of the BChE active site and is almost perpendicular to the axis connecting the entry and the bottom of the active site gorge. Also, it is directed into the area between the Trp82 main chain and Thr120 side chain with which it makes another hydrogen bond via its carbonyl oxygen.
Conclusion
All four compounds reversibly inhibited BChE with inhibition constants ranging from 0.30 μmol/L to 130 μmol/L. The inhibition potency of compounds increased in the following order: 1 < 2 < 4 < 3. AChE was also reversibly inhibited by all compounds with the same order of inhibition potency.
Inhibition constants ranged from 50 μmol/L to 1200 μmol/L. All of the compounds displayed a higher preference for binding to BChE. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 It can be concluded from molecular docking studies that the predicted binding modes of 2-4 in Knowledge of the degree of AChE/BChE selectivity of oxime compounds is may be important for more successful treatment in cases of OP nerve agent poisoning. The most notable pretreatment strategies include protection of the AChE catalytic serine from phosphylating agent by ligands that bind reversibly to AChE [61] [62] [63] [64] [65] and the use of bioscavengers, i.e. BChE, prone to inhibition by a phosphylating agent [66, 67] . Furthermore, BChE is considered to act as a natural bioscavenger in the bloodstream [68, 69] . Considering the especially high degree of preference for binding to BChE displayed by N-substituted 2-hydroxyiminoacetamide 3, our results clearly discourage its use in the protection of the AChE catalytic site from a phosphylating agent by reversible inhibition of AChE.
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